Adagio Medical Holdings, Inc. (Nasdaq: ADGM) announced its financial results for the third quarter ended September 30, 2026, alongside a business update and the initiation of a strategic alternatives review.

Financial results for the quarter showed a net income of $17.8 million, or $2.40 per basic share, compared to a net loss of $10.1 million, or $(19.73) per share, in the prior year period. The company reported no revenue for the three months ended September 30, 2026, with cost of revenue recorded at nil compared to $31,000 in the prior year. Research and development expenses decreased to $1.8 million from $2.8 million, while selling, general, and administrative expenses decreased to $2.6 million from $2.9 million.

The company reported a noncash gain of $23.0 million related to the change in fair value of its 13% Senior Secured Convertible Notes, which drove the net income. Cash and cash equivalents totaled $3.1 million as of September 30, 2026. Additionally, the company effected a one-for-thirty reverse stock split on November 6, 2026, to regain compliance with Nasdaq listing requirements. All share and per-share amounts in the report have been retroactively adjusted to reflect this split.

On the clinical front, Adagio treated a total of 22 patients with its vCLAS Ultra System in the U.S. and Canada. The company highlighted the first patient treated in an Investigational Device Exemption (IDE) sub-study evaluating the next-generation vCLAS Ultra System for Ventricular Tachycardia, initiated at Banner – University Medical Center Phoenix.

Adagio’s Board of Directors initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. The company noted that its PMA application for the vCLAS Ventricular Ablation System remains under FDA review.